CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 300 enrolled
Drug / intervention
Proactive Panel Management Clinics for HFrEFother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05001165
NCT05001165N/ACompleted

Dashboard Activated Services and Tele-Health for Heart Failure

VA Greater Los Angeles Healthcare System·interventional·Posted Aug 11, 2021·Updated Nov 14, 2024

In Brief

A clinical study evaluating Proactive Panel Management Clinics for HFrEF for Heart Failure With Reduced Ejection Fraction. Completed, enrolled 300 participants across 1 site.

Detailed Summary

The Dashboard Activated Services and tele-Health for Heart Failure (DASH-HF) study is a pragmatic randomized controlled trial of a quality improvement (QI) intervention of a prospective panel management intervention to optimize medical treatment for Veterans with heart failure with reduced ejection fraction (HFrEF) compared to the receipt of usual VA health care services over a 6-month period of observation. The study will incorporate the existing VA Academic Detailing Heart Failure Dashboard (ADHFD) to target actionable patients with gaps in performance measures for guideline-directed medical therapies (GDMT). Patients with HFrEF are optimally managed by cardiovascular specialty clinics. Typically, patients are referred to cardiology or heart failure (HF) clinics from primary care, emergency department, or post-hospitalization clinicians and scheduled into clinic grids. These patients may be lost to follow-up or clinicians may miss opportunities to optimize GDMT for HFrEF. GDMT includes Class I indicated medications from the following classes: beta blockers (BB), angiotensin-converting enzyme inhibitor (ACE), angiotensin II receptor blockers (ARB), angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter-2 inhibitor (SGLT2i). The intervention is designed around a novel prospective panel management clinic led by clinicians or clinical pharmacists using impromptu patient telephone calls or electronic communications with existing responsible clinicians.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 11, 2021
Enrollment StartSep 17, 2021
Primary CompletionJun 16, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.9 years ago

Interventions

Proactive Panel Management Clinics for HFrEFother

Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.